G.R.Yin (2008) Hypoglycaemia in patients with type 2 diabetes treated with abination of metformin and sulphonylurea therapy in France Diabetes, Obesity and Metabolism 10 (s1) , 16-24 doi:10.00883.Abstract ORIGINAL ARTICLE HYPOGLYCAEMIA IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH ABINATION OF METFORMIN AND SULPHONYLUREA THERAPY IN FRANCE P.P.G.Lyu and D.Health Oues Research & Health Technology Assessment, Merck & Co.Whitehouse Station, NJ, USADonald Yin, PhD, Merck & Co.One Merck Drive, Whitehouse Station, NJ 08889, USA.Of Diabetology and Endocrinology, Hpital Saint-Louis, Assistance publique - Hpitaux de Paris, Paris, France 2Global Health Oues Research & Health Technology Assessment, Merck & Co.Whitehouse Station, NJ, USA 3Oues Research, Bristol Myers Squibb, Princeton, NJ, USA Donald Yin, PhD, Merck & Co.One Merck Drive, Whitehouse Station, NJ 08889, USA.INTEREST: D.Is an employee and share holder of Merck & Co.M.An employee of Merck & Co.And holds stock of this corporation.L.Employee & share holder of Merck & Co.K.An employee of Merck & Co.The time the paper was written.V.Declared no conflicts of interest.Yet, the impact of hypoglycaemia on quality of life in these patients is not well documented.Examine patient-reported experience of hypoglycaemia, worry about hypoglycaemic symptoms and the impact of hypoglycaemia on patients' quality of life associated with use of sulphonylurea co-administered with metformin.Was an observational, cross-sectional, multi-centre study.Total of 98 primary care centres in France during October to December 2005.Total of 400 patients with type 2 diabetes, who were 35 years old and who had been treated with metformin and a sulphonylurea for at least 6 months,pleted questionnaires during their usual primary care office visit.Measures: Frequency and severity of hypoglycaemic symptoms in the past 6 months, the Worry subscale of the Hypoglycaemic Fear Survey-II (HFS-II) and the EuroQol-5 Dimensions (EQ-5D) questionnaire.Total of 136 (34%) patients reported experiencing hypoglycaemia, of whom 78 (58%) experienced mild, 40 (30%) experienced moderate and 16 (12%) experienced severe or very severe symptoms.On the HFS-II Worry scale was higher for patients who reported having hypoglycaemia than for those who did not (19.10.< 0.With severity of hypoglycaemic symptoms.Linear regression analyses, more severe symptoms of hypoglycaemia were significantly associated with higher scores on the HFS-II Worry scale (p = 0.With hypoglycaemic symptoms.Scores on the EQ-5D were lower for patients who reported hypoglycaemia than for those who did not (p = 0.In multivariate analysis, the experience of hypoglycaemia was negatively associated with the EQ-5D summary score (p < 0.Conclusion: The occurrence and severity of hypoglycaemic symptoms were associated with increased patient worry about hypoglycaemia and lower health-related quality of life among type 2 diabetic patients being treated with both metformin and a sulphonylurea.THIS ARTICLE SEARCH InSynergyPubMed (MEDLINE)CrossRefBy keywordsdiabetesFrancehypoglycaemiametforminquestionnairesulphonylureaworryBy authorP.MavrosG.Read more Affymax and takeda report long-term safety and effectiveness data of hematide in chronic renal failure patients with anemia
Get more Platinum-specific detection and quantification of oxaliplatin and pt(r,r-diaminocyclohexane)cl2 in the blood plasma of colorectal cancer patients
